Kamal D Srivastava1, David Dunkin2, Changda Liu1, Nan Yang1, Rachel L Miller3, Hugh A Sampson1, Xiu-Min Li4. 1. Division of Allergy and Immunology, Department of Pediatrics, The Icahn School of Medicine at Mount Sinai, New York, New York. 2. Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, The Icahn School of Medicine at Mount Sinai, New York, New York. 3. Department of Medicine, Department of Pediatrics, Department of Environmental Health Sciences, Columbia University, New York, New York. 4. Division of Allergy and Immunology, Department of Pediatrics, The Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: xiu-min.li@mssm.edu.
Abstract
BACKGROUND: Neutrophil-predominant asthma is less responsive to steroids and associated with poorer disease control. The effects of Antiasthma Simplified Herbal Medicine Intervention (ASHMI), a traditional Chinese medicine formula reported to be efficacious in asthmatic patients and murine asthma models, on neutrophil predominant asthma are unknown. OBJECTIVE: To determine the effects of standard ASHMI and refined formula ASHMI (ASHMI(II)) in a neutrophil-predominant murine model of ragweed (RW) asthma and explore underlying mechanisms. METHODS: BALB/c mice were systemically sensitized, intranasally challenged with RW extract, and orally treated with ASHMI, ASHMI(II), or vehicle (water). In a separate experiment, some RW sensitized mice were treated with dexamethasone before challenge. After RW challenge, airway hyperreactivity (AHR), total and differential bronchoalveolar lavage fluid leukocyte counts, lung histologic features, and bronchoalveolar lavage fluid cytokine and chemokine levels were assessed. RW stimulation of the murine macrophage cell line RAW264.7 was used to determine effects of ASHMI active compound ganoderic acid C1 (GAC1) on tumor necrosis factor α (TNF-α) production and regulation of phosphorylated IκB and histone deacetylase 2 (HDAC2) levels. RESULTS: ASHMI and ASHMI(II) markedly reduced AHR, mucous production, neutrophilic inflammation, and TNF-α, interleukin 8, and interleukin 17 levels and decreased eosinophilic inflammation and TH2 responses in vivo (P < .01-.001 for all). GAC1 inhibited TNF-α production in RW-stimulated RAW264.7 cells in association with suppression of phosphorylated IκB and increased HDAC2 expression. Dexamethasone failed to reduce AHR and neutrophilic inflammation. CONCLUSION: ASHMI treatment was efficacious in a murine model of neutrophil-predominant asthma via modulation of innate chemokines, TH2 responses, nuclear factor-κB, and HDAC2. ASHMI, and/or its constituent GAC1, may be a valuable option for treating neutrophil-predominant asthma.
BACKGROUND: Neutrophil-predominant asthma is less responsive to steroids and associated with poorer disease control. The effects of Antiasthma Simplified Herbal Medicine Intervention (ASHMI), a traditional Chinese medicine formula reported to be efficacious in asthmatic patients and murineasthma models, on neutrophil predominant asthma are unknown. OBJECTIVE: To determine the effects of standard ASHMI and refined formula ASHMI (ASHMI(II)) in a neutrophil-predominant murine model of ragweed (RW) asthma and explore underlying mechanisms. METHODS: BALB/c mice were systemically sensitized, intranasally challenged with RW extract, and orally treated with ASHMI, ASHMI(II), or vehicle (water). In a separate experiment, some RW sensitized mice were treated with dexamethasone before challenge. After RW challenge, airway hyperreactivity (AHR), total and differential bronchoalveolar lavage fluid leukocyte counts, lung histologic features, and bronchoalveolar lavage fluid cytokine and chemokine levels were assessed. RW stimulation of the murine macrophage cell line RAW264.7 was used to determine effects of ASHMI active compound ganoderic acid C1 (GAC1) on tumor necrosis factor α (TNF-α) production and regulation of phosphorylated IκB and histone deacetylase 2 (HDAC2) levels. RESULTS: ASHMI and ASHMI(II) markedly reduced AHR, mucous production, neutrophilic inflammation, and TNF-α, interleukin 8, and interleukin 17 levels and decreased eosinophilic inflammation and TH2 responses in vivo (P < .01-.001 for all). GAC1 inhibited TNF-α production in RW-stimulated RAW264.7 cells in association with suppression of phosphorylated IκB and increased HDAC2 expression. Dexamethasone failed to reduce AHR and neutrophilic inflammation. CONCLUSION: ASHMI treatment was efficacious in a murine model of neutrophil-predominant asthma via modulation of innate chemokines, TH2 responses, nuclear factor-κB, and HDAC2. ASHMI, and/or its constituent GAC1, may be a valuable option for treating neutrophil-predominant asthma.
Authors: Kazuhiro Ito; Gaetano Caramori; Sam Lim; Tim Oates; K Fan Chung; Peter J Barnes; Ian M Adcock Journal: Am J Respir Crit Care Med Date: 2002-08-01 Impact factor: 21.405
Authors: Mark Hew; Pankaj Bhavsar; Alfons Torrego; Sally Meah; Nadia Khorasani; Peter J Barnes; Ian Adcock; Kian Fan Chung Journal: Am J Respir Crit Care Med Date: 2006-04-13 Impact factor: 21.405
Authors: Changda Liu; Nan Yang; Ying Song; Lixin Wang; Jiachen Zi; Shuwei Zhang; David Dunkin; Paula Busse; David Weir; Jody Tversky; Rachel L Miller; Joseph Goldfarb; Jixun Zhan; Xiu-Min Li Journal: Int Immunopharmacol Date: 2015-05-21 Impact factor: 4.932
Authors: Changda Liu; David Weir; Paula Busse; Nan Yang; Zhenwen Zhou; Charles Emala; Xiu-Min Li Journal: Phytother Res Date: 2015-03-23 Impact factor: 5.878
Authors: Iván López-Expósito; Kamal D Srivastava; Neil Birmingham; Alexandra Castillo; Rachel L Miller; Xiu-Min Li Journal: Ann Allergy Asthma Immunol Date: 2014-11-18 Impact factor: 6.347